Lightnews — Scholar-powered news

Reposted by Max Wolff

the only mikewilson in australia @mikewilsoninoz.bsky.social · 4d

I've been saying that since I was 18, as I exited a Jimi Hendrix concert in Kansas City

1 2

Max Wolff @trpwolff.bsky.social · 5d

psycnet.apa.org/fulltext/202...

1

Max Wolff @trpwolff.bsky.social · 5d

New long-read theory paper in Psychological Review:

Im short, we propose that effective psychedelic therapy employs the uniquely context-dependent effects of psychedelic drugs to engage & augment the same psychological change processes that underlie all effective psychotherapies.

Full text below ⬇️

2 2 9

Max Wolff @trpwolff.bsky.social · 6d

journals.sagepub.com/doi/10.1177/...

Psychedelic-assisted therapy as a complex intervention: implications for clinical trial design - S. D. Muthumaraswamy, M. J. Baggott, E. E. Schenberg, D. Repantis, M. Wolff, A. Forsyth, T. Noorani, 20...

Psychedelic-assisted therapy (PAT) has typically been evaluated using conventional randomised controlled trials (RCTs), which assess treatment efficacy under hi...

journals.sagepub.com

1

Max Wolff @trpwolff.bsky.social · 6d

Classical randomized controlled trials (RCTs) can't capture the complexity of psychedelic therapy.
In this new paper led by @sdmuthu.bsky.social and @tehseennoorani.bsky.social, we argue for pragmatic trials designs that accommodate this complexity and better align with real-world clinical practice.

1 1 4

Max Wolff @trpwolff.bsky.social · 7d

No worries. At least my name is not misspelled in the actual paper like @sdmuthu.bsky.social's! Hope he can get that corrected.

1 2

Reposted by Max Wolff

Eduardo Schenberg, PhD @eeschenberg.bsky.social · 7d

New paper out with @tehseennoorani.bsky.social @maxwolff.bsky.social and orhers, showing that the UK Medical Research Council's framework for complex interventions offer an important way foward for the field of #psychedelics:
journals.sagepub.com/doi/epub/10....

Psychedelic-assisted therapy as a complex intervention: implications for clinical trial design

journals.sagepub.com

1 2 5

Max Wolff @trpwolff.bsky.social · 7d

* @trpwolff.bsky.social

1

Max Wolff @trpwolff.bsky.social · 14d

*psychosocial

Max Wolff @trpwolff.bsky.social · 14d

onlinelibrary.wiley.com/doi/10.1002/...

Has the time come to stop using control groups in trials of psychosocial interventions?

Click on the article title to read more.

onlinelibrary.wiley.com

1 2

Max Wolff @trpwolff.bsky.social · 14d

Has the time come to stop using "control groups" in trials of psychological interventions? — asks Pim Cuijpers.

This discussion concerns psychedelic therapy, which is a (pharmacologically catalyzed) psychological intervention, just as well as any other form of psychotherapy.

Link below.

1 1 5

Max Wolff @trpwolff.bsky.social · 16d

www.sciencedirect.com/science/arti...

Key competencies for psychedelic treatment in real-world mental health care settings

Psychedelic treatments are extending beyond research units and into hospitals, outpatient clinics, and community practices. Contrasting the constraine…

www.sciencedirect.com

1

Max Wolff @trpwolff.bsky.social · 16d

From our recent article "Key competencies for psychedelic treatment in real-world mental health care settings"

Full-text link below.

2 1

Reposted by Max Wolff

Samuli Kangaslampi @kangaslampi.bsky.social · 20d

Recovering memories under MDMA or psychedelics and the impact of The Tell, a few scattered thoughts and observations: kangaslampi.net/the-tell-and...

The Tell and recovered memories under MDMA and psychedelics – Samuli Kangaslampi

kangaslampi.net

1 5

Max Wolff @trpwolff.bsky.social · 24d

www.sciencedirect.com/science/arti...

www.sciencedirect.com

1

Max Wolff @trpwolff.bsky.social · 24d

Our new paper "Key competencies for psychedelic treatment in real-world mental health care settings" has just been published in General Hospital Psychiatry.

Full-text link below.

2 2 11

Reposted by Max Wolff

nicolaslanglitz.bsky.social @nicolaslanglitz.bsky.social · Sep 6

My article "Experiments in medicalization" on the Swiss and Australian efforts to enable psychedelic therapies outside of clinical trials but short of market approval has just come out in BioSocieties: www.nicolaslanglitz.de/ewExternalFi...

www.nicolaslanglitz.de

1 2 3

Max Wolff @trpwolff.bsky.social · Aug 28

If by "hype" you mean the unusually high level of attention this research area gets outside academia, especially from investors and media focused on the business side, then agreed. It is very strange seeing researchers and finance/tech people regularly liking and commenting on each other’s posts.

1

Max Wolff @trpwolff.bsky.social · Aug 28

Thanks, I agree with much of the analysis of Linkedin but I don't think it explains (more or less directly) why the field of psychedelic research seems to have an exceptional affinity to it, compared to other fields. Or?

1 1

Max Wolff @trpwolff.bsky.social · Aug 28

Bluesky now platform of choice for science community - except for the psychedelic science community, which seems to have chosen Linkedin.

What does this say about psychedelic science?

David Shiffman, Ph.D. 🦈 @whysharksmatter.bsky.social · Aug 27

Bluesky now platform of choice for science community - Ars Technica | Media coverage of our new paper

Bluesky now platform of choice for science community

It’s not just you. Survey says: “Twitter sucks now and all the cool kids are moving to Bluesky”…

arstechnica.com

3 5

Reposted by Max Wolff

josh hardman @josh-hardman.bsky.social · Jul 31

BREAKING: German regulators have green-lit the EU's first psilocybin compassionate access program.

Unlike other countries’ pre-approval pathways, Germany’s does not require case-by-case regulatory approval and may see insurers cover costs.

Details: psychedelicalpha.com/news/germany...

Germany Establishes EU’s First Psilocybin Compassionate Access Program - Psychedelic Alpha

Germany has become the first EU country to allow legal access to psilocybin under a compassionate use program for treatment-resistant depression. Unlike other countries’ pre-approval pathways, Germany...

psychedelicalpha.com

3 11

Max Wolff @trpwolff.bsky.social · Jul 26

Out of curiosity, how did you know it was AI-generated? I've also suspected AI involvement in some reviewer comments I've received, but not always sure whether comments were fully AI-generated or only refined using AI.

1 1

Max Wolff @trpwolff.bsky.social · Jul 20

Our recent article "Reframing psychedelic regulation: Tools, not treatments" is discussed on the SPACE blog (in Portuguese): space.com.pt/blogue/regul...

Regulamentar Psicadélicos como Ferramentas, Não como Tratamentos | SPACE Portugal — Sociedade Portuguesa de Aplicação Clínica de Enteógenos

O artigo de Wolff et al. (2025), "Reframing psychedelic regulation: Tools, not treatments", constitui uma contribuição oportuna e...

space.com.pt

3

Reposted by Max Wolff

PAREA @pareascience.bsky.social · Jul 15

Big news for psychedelic research in Europe:

The new €4.3M INTEGRATE project will train 16 PhDs across Europe. Funded by Marie Skłodowska-Curie Actions, it marks a major step forward. PAREA is proud to support by hosting secondments.

More here: parea.eu/parea-news/i...

Europe Invests in the Future of Psychedelic Science: INTEGRATE Doctoral Network Launches with €4.3 Million in Funding — PAREA

A second major EU-funded project in psychedelic science, following PsyPal, will start in the coming months. INTEGRATE will be a doctoral training network supported by €4.3 million in EU funding throug...

parea.eu

4 5

Max Wolff @trpwolff.bsky.social · Jul 11

Small feasibility study testing MDMA-assisted psychotherapy for major depression, unsurprisingly with promising results, from Norway.

www.cambridge.org/core/journal...

1 7